Physician profile
Ossama R Samuel
NPI 1871533109
$6,811.53
in general payments reported to CMS, 2019-2025
25 companies · $1,493 in 2025
The $1,493 reported for 2025 was more than what 82% of Nuclear Cardiology providers received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,071 · 2020: $344 · 2021: $83.03 · 2022: $695 · 2023: $1,120 · 2024: $2,005 · 2025: $1,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,618.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,106.52 | 2019-2024 | Mitraclip, Pressurewire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,045.77 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $636.33 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $622.99 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $508.66 | 2019-2025 | Wainua, Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $472.73 | 2021-2025 | Verquvo |
| Amgen INC. | $402.49 | 2022-2025 | Repatha, Repatha |
| Pfizer INC. | $224.30 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $218.89 | 2019-2024 | Xarelto |
| Terumo Medical Corporation | $173.22 | 2022 | |
| Medtronic, INC. | $171.61 | 2024-2025 | Symplicity G3, Venaseal |
| Medtronic Vascular, INC. | $158.40 | 2020 | |
| Scpharmaceuticals INC. | $145.84 | 2025 | |
| Shockwave Medical, INC | $141.12 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novo Nordisk INC | $124.99 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $107.62 | 2019-2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $102.98 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $97.38 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $94.85 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $81.46 | 2025 | Camzyos, Eliquis |
| Bridgebio Pharma, INC. | $77.89 | 2025 | Attruby |
| Boston Scientific Corporation | $30.37 | 2024 | Varithena Administration Pack |
| Regeneron Healthcare Solutions, INC. | $26.14 | 2019 | |
| Esperion Therapeutics, INC. | $20.00 | 2021 | |
| Gilead Sciences, INC. | $18.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ossama Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.